Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

Summary

SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SPH3127 for the treatment of mild-to-moderate ulcerative colitis.

Timeline

Start

2022-03-21

Primary completion

2022-11-01

Completion

2022-11-01

Outcome

Outcome not reported

Stopped (Enrollment): “Shanghai Pharma Biotherapeutics USA Inc. experienced difficulty in recruiting clinical research sites and in enrolling patients with ulcerative colitis, and consequently, the study was terminated due to futility.”

Drugs

Indications